MCM7 Gene Expression versus Risk of Malignancy Index (RMI) for Prediction of Ovarian Malignancy

Background: Ovarian malignancy is the most common gynecological malignancy after the cancer of the cervix. A woman's risk at birth of ovarian cancer at some time in her life is 1 % to 1.5% and that of dying from cancer is almost 0.5 %. The most commonly occurring ovarian tumors are of epithelial in origin. It has the highest case-fatality ratio of all gynecological malignancies. Hence the early diagnosis is the most important factor for better prognosis. A clinical evaluation of the patient, followed by ultrasonography and CA-125 is helpful. This study aims to determine the role of Risk of Malignancy Index (Jacob’s RMI) in ovarian tumors for prediction of ovarian malignancy.Methods: This is a prospective cohort study. The present study was carried out at department of OBG, in collaboration with the Departments of Radio diagnosis and Pathology, AHRR, New Delhi. 100 patients meeting the inclusion and exclusion criteria were considered. Detailed clinical history, examination and ultrasonography (Abdomen and pelvis) were done. Estimation of CA125 was done thereafter. Calculated JACOBS RMI score was compared with operative surgical staging and histopathological-cytological examination of the specimen. Data obtained thereafter was analysed using appropriate and relevant statistical software.Results: In present study sensitivity of RMI Score in the pre-menopausal women was 66.7% and in post-menopausal women was 83.3%. Specificity of RMI Score in the pre-menopausal women was 96.3% and in post-menopausal women was 81.8%. The positive predictive value in the pre-menopausal women was 40% and in post-menopausal women was 71.4%. The negative predictive value in the pre-menopausal women was 98.7% and in post-menopausal women was 90%. Diagnostic accuracy in a case of premenopausal women was is 95.2% and 82.4% for postmenopausal women.Conclusions: The present study shows that RMI Score helps in identifying effectively those patients who require Staging Laparotomy and hence referral to Gynecologist Oncologist. Patients with ovarian masses with low risk of malignancy index can be treated by minimal access procedures.

Download Full-text

Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial

Journal of Clinical Medicine ◽

10.3390/jcm8111784 ◽

2019 ◽

Vol 8 (11) ◽

pp. 1784 ◽

Cited By ~ 4

Author(s):

Vincent Dochez ◽

Mélanie Randet ◽

Céline Renaudeau ◽

Jérôme Dimet ◽

Aurélie Le Thuaut ◽

...

Keyword(s):

Ovarian Cancer ◽

Likelihood Ratio ◽

Positive Likelihood Ratio ◽

Ovarian Malignancy ◽

Cancer Antigen 125 ◽

Mean Values ◽

Benign Ovarian Tumours ◽

Ovarian Tumours ◽

Risk Of Malignancy ◽

Risk Of Malignancy Index

Background: Presumed benign ovarian tumours (PBOT) are defined by the International Ovarian Tumour Analysis (IOTA) group, without suspected sonographic criteria of cancer, without ascites or metastasis. The aim is to evaluate the efficacy of human epididymis protein 4 (HE4), cancer antigen 125 (CA125), the risk of malignancy index (RMI) and the risk of ovarian malignancy index (ROMA) to predict ovarian cancer in women with PBOT. Methods: It is a prospective, observational, multicentre, laboratory-based study including women with PBOT in four hospitals from 11 May 2015 through 12 May 2016. Preoperative CA125 and HE4 plasma levels were measured for all women. The primary endpoint was the specificity of CA125 and HE4 for diagnosing ovarian cancer. The main secondary endpoints were specificity and likelihood ratio of RMI, ROMA and tumours markers. Results: Two hundred and fifty patients were initially enrolled and 221 patients were finally analysed, including 209 benign ovarian tumours (94.6%) and 12 malignant ovarian tumours (5.4%). The malignant group had significantly higher mean values of HE4, CA125, RMI and ROMA compared to the benign group (p < 0.001). Specificity was significantly higher using a combination of HE4 and CA125 (99.5%) compared to either HE4 or CA125 alone (90.4% and 91.4%, respectively, p < 0.001). Moreover, the positive likelihood ratio for combination HE4 and CA125 was significantly higher (104.5; 95% CI 13.6–800.0) compared to HE4 alone (5.81; 95% CI 2.83–11.90) or CA125 alone (6.97; 95% CI 3.91–12.41). Conclusions: The combination of HE4 and CA125 represents the best tool to predict the risk of ovarian cancer in patients with a PBOT.

Download Full-text

Preoperative predictability of ovarian malignancy using risk of malignancy index

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(06)80540-9 ◽

2006 ◽

Vol 4 (1) ◽

pp. 55

Author(s):

C. Enakpene ◽

P. Fasching ◽

T. Goecke ◽

J. Siemers ◽

W.M. Beckmann

Keyword(s):

Ovarian Malignancy ◽

Risk Of Malignancy ◽

Risk Of Malignancy Index

Download Full-text

Сравнительная оценка алгоритмов дифференциальной диагностики образований яичников (ROMA, RMI)

Ultrasound & Functional Diagnostics ◽

10.24835/1607-0771-2020-2-48-59 ◽

2020 ◽

pp. 48-59

Keyword(s):

Tumor Markers ◽

Ovarian Tumors ◽

Ovarian Malignancy ◽

Risk Of Malignancy ◽

Risk Of Malignancy Index

Цель настоящего исследования - сравнение эффективности алгоритмов ROMA и RMI в прогнозировании злокачественного характера образований яичников. Проведено обследование 188 женщин с одно- или двусторонними образованиями яичников. У 126 (67,0%) пациенток были выявлены доброкачественные образования яичников (первая группа), у 62 (33,0%) - злокачественные (вторая группа). У всех пациенток диагноз был верифицирован по результатам морфологического исследования послеоперационного материала. В первой группе в подгруппе менопаузы было 78 из 126 (61,9%) пациенток, во второй группе - 48 из 62 (77,4%) (P 0,05). При сравнении пациенток с доброкачественными и злокачественными образованиями яичников получены достоверные различия по показателям ROMA и RMI в группах и подгруппах сравнения (P 0,05). Показатель RMI обладает более высокими показателями диагностической эффективности по сравнению с показателем ROMA (AUC, чувствительность и специфичность соответствуют 0,93, 85,5% и 96,8% против 0,89, 87,1% и 83,3% соответственно). Показатель RMI может быть рекомендован в качестве начального этапа дифференциально-диагностического поиска у пациенток с образованиями яичников. Ключевые слова: ультразвуковая диагностика, злокачественные опухоли яичников, онкомаркеры, CA125, HE4, алгоритм расчета риска злокачественного образования яичников (ROMA), индекс риска злокачественности (RMI), ultrasound, malignant ovarian tumors, tumor markers, CA125, HE4, risk of ovarian malignancy algorithm (ROMA), risk of malignancy index (RMI)

Download Full-text

A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.08.025 ◽

2018 ◽

Vol 151 (1) ◽

pp. 159-165 ◽

Cited By ~ 16

Author(s):

Maria Lycke ◽

Björg Kristjansdottir ◽

Karin Sundfeldt

Keyword(s):

Clinical Trial ◽

Ovarian Malignancy ◽

Multicenter Clinical Trial ◽

Risk Of Malignancy ◽

Risk Of Malignancy Index

Download Full-text

OC25.03: A prospective evaluation of the ovarian crescent sign and the risk of malignancy index (RMI) for the diagnosis of ovarian malignancy

Ultrasound in Obstetrics and Gynecology ◽

10.1002/uog.2144 ◽

2005 ◽

Vol 26 (4) ◽

pp. 349-349

Author(s):

J. Yazbek ◽

K. Hillaby ◽

J. Ben Nagi ◽

E. Sawyer ◽

S. Helmy ◽

...

Keyword(s):

Ovarian Malignancy ◽

Prospective Evaluation ◽

Crescent Sign ◽

Risk Of Malignancy ◽

Risk Of Malignancy Index

Download Full-text

The adnexal mass: Benign or malignant? Evaluation of risk of malignancy index

Bangabandhu Sheikh Mujib Medical University Journal ◽

10.3329/bsmmuj.v6i2.29128 ◽

2016 ◽

Vol 6 (2) ◽

pp. 127

Author(s):

Shamsun Nahar ◽

Latifa Shamsuddin

Keyword(s):

Adnexal Mass ◽

Histopathological Examination ◽

Menopausal Status ◽

Abdominal Ultrasound ◽

Ovarian Malignancy ◽

Abdominal Ultrasonography ◽

Serum Ca125 ◽

Risk Of Malignancy ◽

Risk Of Malignancy Index ◽

Ultrasound Score

Background: Screening programme for ovarian malignancy is an international public demand. Ojective: To validate a risk of malignancy index (RMI) incorporating serum CA125, abdominal ultrasound findings and menopausal status for preoperative diagnosis of ovarian malignancy among patient with adnexal mass.Methods: This prospective observational study was conducted on 57 patients having adnexal mass admitted consecutively for surgical exploration in BSMMU from January 2000 to March 2001. S. CA125 assay & abdominal ultrasonography was done within 10 days preoperatively. Ultrasound score (0, 1 & 3) using 5 sonographic features & menopausal score (1 & 3) were calculated. RMI was detected by the formula "RMI = Ultrasound score - Menopausal score - S. CA125 level" Definitive diagnosis was based on histopathological examination.See PDF for the rest of the abstract.

Download Full-text